Recordati traded at 42.91 this Tuesday July 5th, decreasing 0.11 or 0.26 percent since the previous trading session. Looking back, over the last four weeks, Recordati lost 7.71 percent. Over the last 12 months, its price fell by 14.35 percent. Looking ahead, we forecast Recordati to be priced at 41.37 by the end of this quarter and at 36.74 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
42.91
Daily Change
-0.26%
Yearly
-14.35%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Almirall SA 10.87 0.08 0.74% -28.01%
GlaxoSmithKline 1,786.60 -16.00 -0.89% 24.57%
Hikma Pharmaceutical 1,638.00 -16.00 -0.97% -35.94%
Orion 43.72 0.97 2.27% 17.97%
Sanofi 97.12 -1.22 -1.24% 11.93%

Indexes Price Day Year
IT40 20705 -638.87 -2.99% -17.93%

Recordati
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.